JP5136797B2 - Isopropylmethylphenol-containing liquid oral composition - Google Patents
Isopropylmethylphenol-containing liquid oral composition Download PDFInfo
- Publication number
- JP5136797B2 JP5136797B2 JP2008522389A JP2008522389A JP5136797B2 JP 5136797 B2 JP5136797 B2 JP 5136797B2 JP 2008522389 A JP2008522389 A JP 2008522389A JP 2008522389 A JP2008522389 A JP 2008522389A JP 5136797 B2 JP5136797 B2 JP 5136797B2
- Authority
- JP
- Japan
- Prior art keywords
- sodium
- composition
- liquid oral
- isopropylmethylphenol
- polyoxyethylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 70
- 239000007788 liquid Substances 0.000 title claims description 35
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 title claims description 28
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 title claims description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 67
- -1 sodium alkyl sulfate Chemical class 0.000 claims description 57
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 48
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 39
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 36
- 239000011734 sodium Substances 0.000 claims description 25
- 229910052708 sodium Inorganic materials 0.000 claims description 25
- 229920001223 polyethylene glycol Polymers 0.000 claims description 20
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 19
- 239000004359 castor oil Substances 0.000 claims description 18
- 235000019438 castor oil Nutrition 0.000 claims description 18
- 235000011187 glycerol Nutrition 0.000 claims description 18
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 18
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000002202 Polyethylene glycol Substances 0.000 claims description 15
- 150000005215 alkyl ethers Chemical class 0.000 claims description 11
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N N-methylaminoacetic acid Natural products C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000000080 wetting agent Substances 0.000 claims description 9
- 108010077895 Sarcosine Proteins 0.000 claims description 8
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 claims description 8
- 229940043230 sarcosine Drugs 0.000 claims description 8
- 229960003500 triclosan Drugs 0.000 claims description 8
- 239000003945 anionic surfactant Substances 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 239000002736 nonionic surfactant Substances 0.000 claims description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 30
- 230000000844 anti-bacterial effect Effects 0.000 description 24
- 238000002156 mixing Methods 0.000 description 17
- 210000000214 mouth Anatomy 0.000 description 17
- 239000000047 product Substances 0.000 description 15
- 239000000126 substance Substances 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 13
- 239000003205 fragrance Substances 0.000 description 12
- 230000007794 irritation Effects 0.000 description 12
- 239000002324 mouth wash Substances 0.000 description 12
- 229940051866 mouthwash Drugs 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000001509 sodium citrate Substances 0.000 description 8
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 230000003204 osmotic effect Effects 0.000 description 7
- 239000004094 surface-active agent Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 230000001771 impaired effect Effects 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000000149 penetrating effect Effects 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 229920000139 polyethylene terephthalate Polymers 0.000 description 4
- 239000005020 polyethylene terephthalate Substances 0.000 description 4
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 4
- 238000005063 solubilization Methods 0.000 description 4
- 230000007928 solubilization Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000000811 xylitol Substances 0.000 description 4
- 235000010447 xylitol Nutrition 0.000 description 4
- 229960002675 xylitol Drugs 0.000 description 4
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical class C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 3
- 241000186046 Actinomyces Species 0.000 description 3
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 3
- 208000025157 Oral disease Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229960000458 allantoin Drugs 0.000 description 3
- 229960003237 betaine Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000417 fungicide Substances 0.000 description 3
- 230000002070 germicidal effect Effects 0.000 description 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 3
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 3
- 208000030194 mouth disease Diseases 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 230000003239 periodontal effect Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108700004121 sarkosyl Proteins 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- XHXUANMFYXWVNG-ADEWGFFLSA-N (-)-Menthyl acetate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(C)=O XHXUANMFYXWVNG-ADEWGFFLSA-N 0.000 description 2
- ULDHMXUKGWMISQ-SECBINFHSA-N (-)-carvone Chemical compound CC(=C)[C@@H]1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-SECBINFHSA-N 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 2
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 2
- NGOZDSMNMIRDFP-UHFFFAOYSA-N 2-[methyl(tetradecanoyl)amino]acetic acid Chemical compound CCCCCCCCCCCCCC(=O)N(C)CC(O)=O NGOZDSMNMIRDFP-UHFFFAOYSA-N 0.000 description 2
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
- INAXVXBDKKUCGI-UHFFFAOYSA-N 4-hydroxy-2,5-dimethylfuran-3-one Chemical compound CC1OC(C)=C(O)C1=O INAXVXBDKKUCGI-UHFFFAOYSA-N 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
- GHBSPIPJMLAMEP-UHFFFAOYSA-N 6-pentyloxan-2-one Chemical compound CCCCCC1CCCC(=O)O1 GHBSPIPJMLAMEP-UHFFFAOYSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108010001682 Dextranase Proteins 0.000 description 2
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 241000282320 Panthera leo Species 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229960002684 aminocaproic acid Drugs 0.000 description 2
- 239000002280 amphoteric surfactant Substances 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical group CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000000855 fungicidal effect Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- JARKCYVAAOWBJS-UHFFFAOYSA-N hexanal Chemical compound CCCCCC=O JARKCYVAAOWBJS-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- MLFHJEHSLIIPHL-UHFFFAOYSA-N isoamyl acetate Chemical compound CC(C)CCOC(C)=O MLFHJEHSLIIPHL-UHFFFAOYSA-N 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- IFYYFLINQYPWGJ-UHFFFAOYSA-N n-hexyl-gamma-butyrolactone Natural products CCCCCCC1CCC(=O)O1 IFYYFLINQYPWGJ-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229940085605 saccharin sodium Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000011775 sodium fluoride Substances 0.000 description 2
- 235000013024 sodium fluoride Nutrition 0.000 description 2
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 2
- 229950005425 sodium myristyl sulfate Drugs 0.000 description 2
- 235000019830 sodium polyphosphate Nutrition 0.000 description 2
- UPUIQOIQVMNQAP-UHFFFAOYSA-M sodium;tetradecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCOS([O-])(=O)=O UPUIQOIQVMNQAP-UHFFFAOYSA-M 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 229960000401 tranexamic acid Drugs 0.000 description 2
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 2
- 239000001974 tryptic soy broth Substances 0.000 description 2
- 108010050327 trypticase-soy broth Proteins 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- MBDOYVRWFFCFHM-SNAWJCMRSA-N (2E)-hexenal Chemical compound CCC\C=C\C=O MBDOYVRWFFCFHM-SNAWJCMRSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- 239000001605 (5-methyl-2-propan-2-ylcyclohexyl) acetate Substances 0.000 description 1
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- HNAGHMKIPMKKBB-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1CC1=CC=CC=C1 HNAGHMKIPMKKBB-UHFFFAOYSA-N 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-N 1-hexadecylpyridin-1-ium;hydrochloride Chemical compound Cl.CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- LFJJOPDNPVFCNZ-UHFFFAOYSA-N 2-[hexadecanoyl(methyl)amino]acetic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N(C)CC(O)=O LFJJOPDNPVFCNZ-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- JMBXKGABBKJKFO-UHFFFAOYSA-N C(OC1(CCC(CC1)C(C)C)C)(=O)OCCO Chemical compound C(OC1(CCC(CC1)C(C)C)C)(=O)OCCO JMBXKGABBKJKFO-UHFFFAOYSA-N 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- XHXUANMFYXWVNG-UHFFFAOYSA-N D-menthyl acetate Natural products CC(C)C1CCC(C)CC1OC(C)=O XHXUANMFYXWVNG-UHFFFAOYSA-N 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 240000002943 Elettaria cardamomum Species 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- YIKYNHJUKRTCJL-UHFFFAOYSA-N Ethyl maltol Chemical compound CCC=1OC=CC(=O)C=1O YIKYNHJUKRTCJL-UHFFFAOYSA-N 0.000 description 1
- VUNOFAIHSALQQH-UHFFFAOYSA-N Ethyl menthane carboxamide Chemical compound CCNC(=O)C1CC(C)CCC1C(C)C VUNOFAIHSALQQH-UHFFFAOYSA-N 0.000 description 1
- 244000061408 Eugenia caryophyllata Species 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 241000208690 Hamamelis Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- LQKRYVGRPXFFAV-UHFFFAOYSA-N Phenylmethylglycidic ester Chemical compound CCOC(=O)C1OC1(C)C1=CC=CC=C1 LQKRYVGRPXFFAV-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000605862 Porphyromonas gingivalis Species 0.000 description 1
- 241000023506 Porphyromonas gingivalis ATCC 33277 Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000194026 Streptococcus gordonii Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N Taurine Natural products NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- UJNOLBSYLSYIBM-WISYIIOYSA-N [(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl] (2r)-2-hydroxypropanoate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)[C@@H](C)O UJNOLBSYLSYIBM-WISYIIOYSA-N 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- JVOGSHDZLOJKKR-MXFMKSRJSA-I [Na+].[Na+].[Na+].[Mg++].CCc1c(C)c2cc3[n-]c(c(C)c3C=C)c(C)c3nc(C[C@H]3CCC([O-])=O)c(CC([O-])=O)c3[n-]c(cc1n2)c(C)c3C([O-])=O Chemical compound [Na+].[Na+].[Na+].[Mg++].CCc1c(C)c2cc3[n-]c(c(C)c3C=C)c(C)c3nc(C[C@H]3CCC([O-])=O)c(CC([O-])=O)c3[n-]c(cc1n2)c(C)c3C([O-])=O JVOGSHDZLOJKKR-MXFMKSRJSA-I 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002882 anti-plaque Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 235000013532 brandy Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000005300 cardamomo Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Natural products CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940108925 copper gluconate Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Polymers OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- SMVRDGHCVNAOIN-UHFFFAOYSA-L disodium;1-dodecoxydodecane;sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O.CCCCCCCCCCCCOCCCCCCCCCCCC SMVRDGHCVNAOIN-UHFFFAOYSA-L 0.000 description 1
- YVIGPQSYEAOLAD-UHFFFAOYSA-L disodium;dodecyl phosphate Chemical compound [Na+].[Na+].CCCCCCCCCCCCOP([O-])([O-])=O YVIGPQSYEAOLAD-UHFFFAOYSA-L 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 229940093503 ethyl maltol Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229940073505 ethyl vanillin Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 108010000165 exo-1,3-alpha-glucanase Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- IFYYFLINQYPWGJ-VIFPVBQESA-N gamma-Decalactone Natural products CCCCCC[C@H]1CCC(=O)O1 IFYYFLINQYPWGJ-VIFPVBQESA-N 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 229960001269 glycine hydrochloride Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940117955 isoamyl acetate Drugs 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 229960002064 kanamycin sulfate Drugs 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 229930007503 menthone Natural products 0.000 description 1
- 229940102398 methyl anthranilate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000001627 myristica fragrans houtt. fruit oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 108700009886 palmitoyl sarcosine Proteins 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229940113115 polyethylene glycol 200 Drugs 0.000 description 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229940057847 polyethylene glycol 600 Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- AZJPTIGZZTZIDR-UHFFFAOYSA-L rose bengal Chemical compound [K+].[K+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 AZJPTIGZZTZIDR-UHFFFAOYSA-L 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000010670 sage oil Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940080236 sodium cetyl sulfate Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000020354 squash Nutrition 0.000 description 1
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 1
- 229960002799 stannous fluoride Drugs 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 239000010678 thyme oil Substances 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- VXYADVIJALMOEQ-UHFFFAOYSA-K tris(lactato)aluminium Chemical compound CC(O)C(=O)O[Al](OC(=O)C(C)O)OC(=O)C(C)O VXYADVIJALMOEQ-UHFFFAOYSA-K 0.000 description 1
- 239000006150 trypticase soy agar Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000012711 vitamin K3 Nutrition 0.000 description 1
- 239000011652 vitamin K3 Substances 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/463—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfuric acid derivatives, e.g. sodium lauryl sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本発明は、歯周病原性バイオフィルムに対する高い浸透殺菌効果を発揮し、かつ低温及び高温保存時における経時での外観安定性が良好で、使用時、使用後の口腔内のべたつき感が低く、低刺激の実質的にエタノールを含有しないことを特徴とするイソプロピルメチルフェノール含有液体口腔用組成物に関する。 The present invention exhibits a high penetrating and bactericidal effect on periodontopathic biofilms, and has good appearance stability over time when stored at low and high temperatures, and when used, has a low stickiness in the oral cavity after use, The present invention relates to an isopropylmethylphenol-containing liquid oral composition characterized by being substantially free from ethanol.
従来、う蝕、歯肉炎、歯周炎及び口臭等の原因は、プラーク中の各種細菌によるものと考えられ、口腔内疾患の予防、改善に有効な手段として、プラークコントロール、即ち、口腔内細菌数を低レベルに保つことが有用であるといわれている。 Conventionally, the causes of caries, gingivitis, periodontitis and bad breath are considered to be caused by various bacteria in plaque. Plaque control, that is, oral bacteria, is an effective means for prevention and improvement of oral diseases. It is said that it is useful to keep the number low.
口腔内の病原性細菌数を低下させる手段としては、非イオン性殺菌剤やカチオン性殺菌剤を口腔ケア製品に配合することが有効な手段となっている。特に、口腔ケア製品に配合される殺菌剤の中でイソプロピルメチルフェノール等の非イオン性殺菌剤は、カチオン性殺菌剤と比較して抗菌スペクトルが広い傾向にある特徴を有することから、口腔用組成物に配合され、上市されている。 As a means for reducing the number of pathogenic bacteria in the oral cavity, it is an effective means to add a nonionic fungicide or a cationic fungicide to the oral care product. In particular, nonionic germicides such as isopropylmethylphenol among the germicides blended in oral care products have characteristics that tend to have a broad antibacterial spectrum compared to cationic germicides. It is blended into products and marketed.
しかしながら、これら非イオン性殺菌剤は油溶性の化合物であり、そのままでは水にほとんど溶けないため、各種界面活性剤及びエタノールなどの溶剤を配合して可溶化させているが、中でも界面活性剤は、殺菌剤の活性化部位を不活性化するため、配合量が増加すると十分な殺菌力が発現されず、また殺菌力向上のため界面活性剤の配合量を減じると低温及び高温にて経時で液が白濁し、組成物の外観安定性が損なわれるという課題があった。 However, these nonionic disinfectants are oil-soluble compounds and are hardly soluble in water as they are, so they are solubilized by blending various surfactants and solvents such as ethanol. In order to inactivate the activation site of the bactericidal agent, if the blending amount is increased, sufficient bactericidal power is not expressed, and if the blending amount of the surfactant is decreased to improve bactericidal power, the temperature is lowered over time at low and high temperatures. There was a problem that the liquid became cloudy and the appearance stability of the composition was impaired.
一方、可溶化溶剤として使用されるエタノールの配合は、口腔用組成物使用時のぴりぴりとした刺激感を引き起こすため、近年、エタノールを配合しないノンアルコール洗口剤の普及が進んできた。しかし、エタノール無配合で、非イオン性殺菌剤を含有する液体口腔用組成物は、エタノール配合時よりも界面活性剤による可溶化力が必要となり、組成物の殺菌力と低温及び高温保存時における経時での外観安定性を両立させることはより困難であった。 On the other hand, the blending of ethanol used as a solubilizing solvent causes a spicy irritating feeling when using the oral composition, and in recent years, non-alcohol mouthwashes that do not contain ethanol have been widely used. However, the composition for liquid oral cavity containing no ionic disinfectant without ethanol is required to have a solubilizing power with a surfactant than when it is combined with ethanol. It was more difficult to achieve both appearance stability over time.
イソプロピルメチルフェノールは、歯周病原性バイオフィルムへの浸透殺菌効果が高い殺菌製剤として注目されている非イオン性殺菌剤である。これまで、イソプロピルメチルフェノールを使用して口腔疾患を予防させる技術では、イソプロピルメチルフェノールを低濃度ポリオキシエチレン硬化ヒマシ油で可溶化しているが(特開昭62−24010号公報、特開平1−305021号公報、特開平7−48237号公報、特開平10−330230号公報:特許文献1〜4参照)、これら組成はいずれもエタノールを含有するため刺激性が高いといった不具合点があった。 Isopropylmethylphenol is a nonionic bactericidal agent that is attracting attention as a bactericidal preparation with a high penetration bactericidal effect on periodontopathic biofilms. Until now, in the technique for preventing oral disease using isopropylmethylphenol, isopropylmethylphenol is solubilized with low-concentration polyoxyethylene hydrogenated castor oil (Japanese Patent Laid-Open Nos. 62-24010 and 1). No.-305021, JP-A-7-482237, JP-A-10-330230: see Patent Documents 1 to 4), and all of these compositions have ethanol, and thus have high irritation.
また、高濃度の湿潤剤を配合し、製剤中の含水率を40%以下にしたり(特開平11−322554号公報:特許文献5参照)、水分量をポリオール類配合量の半分以下に調整して配合したり(特開2001−199854号公報:特許文献6参照)してイソプロピルメチルフェノールの経日安定性、殺菌活性を確保することが提案されている。しかし、これらの技術は、含水量が低いため組成物の粘度が高く洗口に適さない、又は使用後の口腔内でのべたつき感がひどく嗜好性に劣るという不具合点があった。 In addition, a high-concentration wetting agent is blended so that the moisture content in the preparation is 40% or less (see JP-A-11-322554: Patent Document 5), or the water content is adjusted to half or less of the blended amount of polyols. (See JP 2001-199854 A: Patent Document 6) to secure the aging stability and bactericidal activity of isopropylmethylphenol. However, these techniques have a drawback in that the water content is low and the composition has a high viscosity and is not suitable for mouth washing, or the stickiness in the oral cavity after use is extremely poor.
本発明は、上記事情に鑑みなされたもので、歯周病原性バイオフィルムに対する高い浸透殺菌効果を発揮し、かつ低温及び高温保存時における経時での外観安定性が良好で、使用時、使用後の口腔内のべたつき感が低く、低刺激である、イソプロピルメチルフェノールを含有し、実質的にエタノールを含有しない液体口腔用組成物を提供することを目的とする。 The present invention has been made in view of the above circumstances, exhibits a high penetrating bactericidal effect on periodontopathic biofilms, and has good appearance stability over time during storage at low and high temperatures. An object of the present invention is to provide a liquid oral composition containing isopropylmethylphenol and having substantially no ethanol, which is low in stickiness in the oral cavity and low in irritation.
本発明者らは、上記目的を達成するため鋭意研究を重ねた結果、殺菌成分としてイソプロピルメチルフェノールを含有する液体口腔用組成物に、アルキル硫酸ナトリウム及びN−アシルサルコシンナトリウムから選ばれる少なくとも1種のアニオン性界面活性剤と、エチレンオキサイドの平均付加モル数が40〜100モルのポリオキシエチレン硬化ヒマシ油及び炭素鎖長が16〜18でエチレンオキサイドの平均付加モル数が10〜40モルのポリオキシエチレンアルキルエーテルから選ばれる少なくとも1種の非イオン性界面活性剤とを配合し、更にグリセリン、プロピレングリコール、ブチレングリコール、及び平均分子量190〜630のポリエチレングリコールから選ばれる少なくとも1種の湿潤剤を組成物全体の5〜15質量%併用し、かつ組成物中の水分量を70質量%以上にすることにより、歯周病原性バイオフィルムに対する高い浸透殺菌効果が発揮され、高温及び低温保存時においても外観安定性が良好で、かつ使用時、使用後の口腔内のべたつき感が低く、低刺激である、実質的にエタノールを含有しない液体口腔用組成物が得られ、更に、この液体口腔用組成物にトリクロサンを配合することにより、浮遊菌に対する殺菌効果が向上することを見出した。 As a result of intensive studies to achieve the above object, the present inventors have found that liquid oral compositions containing isopropylmethylphenol as a bactericidal component are at least one selected from sodium alkyl sulfate and sodium N-acyl sarcosine. Anionic surfactants, polyoxyethylene hydrogenated castor oil having an average added mole number of ethylene oxide of 40 to 100 moles, and a polyoxyethylene having an average added mole number of ethylene oxide of 16 to 18 and ethylene oxide. And at least one nonionic surfactant selected from oxyethylene alkyl ethers, and at least one wetting agent selected from glycerin, propylene glycol, butylene glycol, and polyethylene glycol having an average molecular weight of 190 to 630. 5-15% by mass of the total composition And by making the water content in the composition 70% by mass or more, a high penetration bactericidal effect on periodontopathic biofilms is exhibited, and appearance stability is good even at high and low temperature storage, and When used, a liquid oral composition that is low in irritation after use and low in irritation and substantially free of ethanol is obtained, and further, by adding triclosan to this liquid oral composition It was found that the bactericidal effect against airborne bacteria is improved.
本発明によれば、上記特定成分を組み合わせて配合することにより、イソプロピルメチルフェノールを含有する液体口腔用組成物において、実質的にエタノールを含有しない組成で、歯周病原性バイオフィルム中の歯周病菌などの口腔内細菌への優れた殺菌力、低温及び高温保存時における経時での優れた外観安定性、洗口時や洗口後の口腔内のべたつき感が低い優れた使用感を兼ね備え、口腔内疾患の予防、改善効果に優れた高品質の液体口腔用組成物が得られることを知見し、本発明をなすに至った。 According to the present invention, in the liquid oral composition containing isopropylmethylphenol, by blending the specific components in combination, the composition containing substantially no ethanol, the periodontal in the periodontopathic biofilm Combines excellent bactericidal power against oral bacteria such as pathogens, excellent appearance stability over time when stored at low and high temperatures, and excellent usability with low stickiness in mouth after mouthwash and after mouthwash, The present inventors have found that a high-quality liquid composition for oral cavity that is excellent in preventing and improving oral diseases can be obtained.
従って、本発明は、
[I]イソプロピルメチルフェノールが配合された液体口腔用組成物であって、
(A)アルキル硫酸ナトリウム及びN−アシルサルコシンナトリウムから選ばれる少なくとも1種のアニオン性界面活性剤、
(B)エチレンオキサイドの平均付加モル数が40〜100モルのポリオキシエチレン硬化ヒマシ油及び炭素鎖長が16〜18でエチレンオキサイドの平均付加モル数が10〜40モルのポリオキシエチレンアルキルエーテルから選ばれる少なくとも1種の非イオン性界面活性剤、
(C)グリセリン、プロピレングリコール、ブチレングリコール、及び平均分子量190〜630のポリエチレングリコールから選ばれる少なくとも1種の湿潤剤を組成物全体の5〜15質量%
を含有し、かつ組成物中の水分量が70質量%以上であると共に、組成物中のエタノール量が100ppm以下であることを特徴とする液体口腔用組成物
[II]成分(A)が、炭素鎖長が12〜14のアルキル硫酸ナトリウム及びN−アシルサルコシンナトリウムから選ばれる少なくとも1種であり、成分(B)が、エチレンオキサイドの平均付加モル数が60〜100モルのポリオキシエチレン硬化ヒマシ油及び炭素鎖長が16〜18のアルキル鎖を有し、エチレンオキサイドの平均付加モル数が20〜40モルのポリオキシエチレンアルキルエーテルから選ばれる少なくとも1種である[I]記載の液体口腔用組成物
[III]更に、(D)トリクロサンを含有することを特徴とする[I]又は[II]記載の液体口腔用組成物
を提供する。
Therefore, the present invention
[I] A liquid oral composition containing isopropylmethylphenol,
(A) at least one anionic surfactant selected from sodium alkyl sulfate and sodium N-acyl sarcosine,
(B) From polyoxyethylene hydrogenated castor oil having an average addition mole number of ethylene oxide of 40 to 100 moles and polyoxyethylene alkyl ether having a carbon chain length of 16 to 18 and an average addition mole number of ethylene oxide of 10 to 40 moles At least one nonionic surfactant selected,
(C) At least one wetting agent selected from glycerin, propylene glycol, butylene glycol, and polyethylene glycol having an average molecular weight of 190 to 630 is 5 to 15% by mass of the total composition.
And a liquid oral composition [II] component (A) characterized in that the amount of water in the composition is 70% by mass or more and the amount of ethanol in the composition is 100 ppm or less , Polyoxyethylene hydrogenated castor having at least one selected from sodium alkyl sulfate having a carbon chain length of 12 to 14 and sodium N-acyl sarcosine, wherein component (B) has an average added mole number of ethylene oxide of 60 to 100 mol Liquid and oral cavity according to [I], which has at least one selected from polyoxyethylene alkyl ethers having an oil and an alkyl chain with a carbon chain length of 16 to 18 and an average addition mole number of ethylene oxide of 20 to 40 moles Composition [III] The liquid oral composition according to [I] or [II], further comprising (D) triclosan That.
本発明の液体口腔用組成物は、歯周病原性バイオフィルムに対する浸透殺菌効果を発揮すると共に、低温及び高温保存時の経時での外観安定性が良好で、使用時、使用後のべたつき感が低く、低刺激なものである。 The liquid oral composition of the present invention exhibits an osmotic and bactericidal effect on periodontopathic biofilms, has good appearance stability over time during storage at low and high temperatures, and has a sticky feeling after use during use. It is low and hypoallergenic.
以下、本発明につき更に詳細に説明すると、本発明の液体口腔用組成物は、殺菌成分としてイソプロピルメチルフェノールを含有し、アニオン性界面活性剤として(A)アルキル硫酸ナトリウム及びN−アシルサルコシンナトリウムから選ばれる少なくとも1種、非イオン性界面活性剤として(B)エチレンオキサイドの平均付加モル数が40〜100モルのポリオキシエチレン硬化ヒマシ油及び炭素鎖長が16〜18でエチレンオキサイドの平均付加モル数が10〜40モルのポリオキシエチレンアルキルエーテルから選ばれる少なくとも1種、湿潤剤として(C)グリセリン、プロピレングリコール、ブチレングリコール、及び平均分子量190〜630のポリエチレングリコールから選ばれる少なくとも1種を組成物全体の5〜15質量%含有し、かつ組成物中の水分量が70質量%以上であり、実質的にエタノールを含まないものであることを特徴とする。 Hereinafter, the present invention will be described in more detail. The liquid oral composition of the present invention contains isopropylmethylphenol as a bactericidal component, and (A) sodium alkyl sulfate and N-acyl sarcosine sodium as an anionic surfactant. At least one selected as a nonionic surfactant, (B) polyoxyethylene hydrogenated castor oil having an average addition mole number of ethylene oxide of 40 to 100 moles and an average addition mole of ethylene oxide having a carbon chain length of 16 to 18 Composition of at least one selected from polyoxyethylene alkyl ethers having a number of 10 to 40 moles, and (C) glycerin, propylene glycol, butylene glycol, and polyethylene glycol having an average molecular weight of 190 to 630 as a wetting agent 5-15 quality of the whole thing % Contained, and it is the water content in the composition is 70 mass% or more, characterized in that substantially free of ethanol.
本発明で使用される成分(A)のアニオン性界面活性剤としては、歯周病原性バイオフィルムに対する浸透殺菌力及び味及び刺激の点から、アルキル硫酸ナトリウム、N−アシルサルコシンナトリウムから選ばれる少なくとも1種を使用する。これらの中では、歯周病原性バイオフィルムに対する浸透殺菌力及びイソプロピルメチルフェノール可溶化の点で、炭素鎖長が12〜14のアルキル硫酸ナトリウム及びN−アシルサルコシンナトリウムから選ばれるものが好ましく、特にラウリル硫酸ナトリウム、ラウロイルサルコシンナトリウムが好ましく使用される。 The anionic surfactant of the component (A) used in the present invention is at least selected from sodium alkyl sulfate and sodium N-acyl sarcosine from the viewpoint of osmotic bactericidal power against periodontal pathogenic biofilm and taste and irritation. Use one. Among these, those selected from sodium alkyl sulfate and sodium N-acyl sarcosine having a carbon chain length of 12 to 14 are preferable in terms of osmotic bactericidal power against periodontal pathogenic biofilms and solubilization of isopropylmethylphenol. Sodium lauryl sulfate and sodium lauroyl sarcosine are preferably used.
成分(A)の総配合量は、歯周病原性バイオフィルムに対する浸透殺菌力及びイソプロピルメチルフェノール可溶化の点で、好ましくは組成物全体の0.05〜1.0%(質量%、以下同じ)、より好ましくは0.05〜0.5%が好適である。配合量が0.05%未満であると白濁し、高温での外観安定性を損ねる場合があり、1.0%を超えると低温保存時に経時で析出したり、刺激が生じたり、味が悪くなる場合がある。 The total amount of component (A) is preferably 0.05 to 1.0% (mass%, the same applies hereinafter) of the whole composition in terms of osmotic sterilization power to periodontopathic biofilm and solubilization of isopropylmethylphenol. ), More preferably 0.05 to 0.5%. If the blending amount is less than 0.05%, it may become cloudy and impair the stability of appearance at high temperatures. If it exceeds 1.0%, it will precipitate over time during storage at low temperatures, cause irritation, and have poor taste. There is a case.
本発明で使用される成分(B)の非イオン性界面活性剤としては、歯周病原性バイオフィルムに対する浸透殺菌力及び味の点から、エチレンオキサイドの平均付加モル数が40〜100モルのポリオキシエチレン硬化ヒマシ油及び炭素鎖長が16〜18のアルキル鎖を有し、エチレンオキサイドの平均付加モル数が10〜40モルのポリオキシエチレンアルキルエーテルから選ばれる少なくとも1種を使用する。ポリオキシエチレンアルキルエーテルとしては、刺激の点からも平均付加モル数が10〜40モルであるものが用いられる。これらの中では、歯周病原性バイオフィルムに対する浸透殺菌力及びイソプロピルメチルフェノール可溶化の点で、エチレンオキサイドの平均付加モル数が60〜100モルのポリオキシエチレン硬化ヒマシ油、炭素鎖長が16〜18のアルキル鎖を有し、エチレンオキサイドの平均付加モル数が20〜40モルのポリオキシエチレンアルキルエーテルが好ましく使用される。更に、低刺激性の点から、エチレンオキサイドの平均付加モル数が60〜100モルのポリオキシエチレン硬化ヒマシ油が特に好ましく使用される。ポリオキシエチレン硬化ヒマシ油のエチレンオキサイドの平均付加モル数が40モル未満では、低温保存時に析出してしまい、100モルを超えるものは一般に市販されていない。ポリオキシエチレンアルキルエーテルの平均付加モル数が10モル未満では、上記と同様に低温保存時に析出してしまい、かつ刺激が強く、40モルを超えるものは一般には市販されていない。また、上記ポリオキシエチレンアルキルエーテルにおいて、そのアルキル鎖長が16未満では、苦味や刺激が強く、18を超えるものは低温又は高温での外観安定性に劣る。 As the nonionic surfactant of the component (B) used in the present invention, polyene having an average added mole number of ethylene oxide of 40 to 100 moles from the viewpoint of osmotic bactericidal power and taste for periodontopathic biofilms. At least one selected from oxyethylene hydrogenated castor oil and a polyoxyethylene alkyl ether having an alkyl chain having a carbon chain length of 16 to 18 and an average added mole number of ethylene oxide of 10 to 40 mol is used. As the polyoxyethylene alkyl ether, those having an average added mole number of 10 to 40 moles are used from the viewpoint of stimulation. Among these, polyoxyethylene hydrogenated castor oil having an average added mole number of ethylene oxide of 60 to 100 moles and a carbon chain length of 16 in terms of penetrating bactericidal power against periodontopathic biofilm and solubilization of isopropylmethylphenol. A polyoxyethylene alkyl ether having an alkyl chain of ˜18 and an average addition mole number of ethylene oxide of 20 to 40 mol is preferably used. Furthermore, polyoxyethylene hydrogenated castor oil having an average added mole number of ethylene oxide of 60 to 100 mol is particularly preferably used from the viewpoint of low irritation. If the average added mole number of ethylene oxide of polyoxyethylene hydrogenated castor oil is less than 40 moles, it will precipitate during low-temperature storage, and those exceeding 100 moles are generally not commercially available. If the average added mole number of polyoxyethylene alkyl ether is less than 10 moles, it will precipitate during low-temperature storage as described above, and will be strongly irritating, and those exceeding 40 moles are generally not commercially available. Moreover, in the said polyoxyethylene alkyl ether, when the alkyl chain length is less than 16, bitterness and irritation | stimulation are strong, and the thing exceeding 18 is inferior to the external appearance stability in low temperature or high temperature.
成分(B)の総配合量は、歯周病原性バイオフィルムに対する浸透殺菌力及びイソプロピルメチルフェノール可溶化の点で、好ましくは組成物全体の0.1〜1.0%、より好ましくは0.2〜0.7%である。配合量が0.1%未満では低温及び高温での外観安定性を維持するのが難しい場合があり、1.0%を超えると、殺菌力が損なわれる場合がある。成分(B)としてポリオキシエチレンアルキルエーテルを用いた場合、配合量が1.0%を超えると刺激が生じる場合がある。 The total amount of component (B) is preferably from 0.1 to 1.0% of the total composition, more preferably from the viewpoint of osmotic sterilization power to periodontopathic biofilm and solubilization of isopropylmethylphenol. 2 to 0.7%. If the blending amount is less than 0.1%, it may be difficult to maintain the appearance stability at low and high temperatures, and if it exceeds 1.0%, the sterilizing power may be impaired. When polyoxyethylene alkyl ether is used as the component (B), irritation may occur if the blending amount exceeds 1.0%.
本発明で使用される成分(C)の湿潤剤としては、グリセリン、プロピレングリコール、ブチレングリコール、及び平均分子量190〜630のポリエチレングリコールから選ばれる少なくとも1種を使用する。 As the wetting agent of component (C) used in the present invention, at least one selected from glycerin, propylene glycol, butylene glycol, and polyethylene glycol having an average molecular weight of 190 to 630 is used.
なお、上述した平均分子量は、化粧品原料基準(第2版注解)記載の平均分子量を示し、平均分子量190〜630のポリエチレングリコールとしては、ポリエチレングリコール200(平均分子量190〜210)、ポリエチレングリコール300(平均分子量280〜320)、ポリエチレングリコール400(平均分子量380〜420)、ポリエチレングリコール600(平均分子量570〜630)が該当する。商品によっては、例えばポリエチレングリコール#200のように、ポリエチレングリコールと数値の間に#がつく場合がある。 In addition, the average molecular weight mentioned above shows the average molecular weight described in cosmetic raw material standards (2nd edition comment), and polyethylene glycol 200 (average molecular weight 190-210), polyethylene glycol 300 (average molecular weight 190-630) The average molecular weight 280-320), polyethylene glycol 400 (average molecular weight 380-420), and polyethylene glycol 600 (average molecular weight 570-630) are applicable. Depending on the product, for example, polyethylene glycol # 200, there may be a # between polyethylene glycol and the numerical value.
更に、成分(C)は、低温での外観安定性及び使用時の味の点から2種以上用いることが好ましく、更に高温での外観安定性の点から3種以上用いることがより好ましい。2種の組合せとしては、グリセリンとプロピレングリコール、グリセリンとブチレングリコール、グリセリンとポリエチレングリコール(特にポリエチレングリコール#400)の組み合わせが好ましい。また、3種の組み合わせとしては、グリセリンとプロピレングリコールとポリエチレングリコール、グリセリンとプロピレングリコールとブチレングリコールの組み合わせが好ましい。 Furthermore, it is preferable to use 2 or more types of a component (C) from the point of the external appearance stability in low temperature and the taste at the time of use, and it is more preferable to use 3 or more types from the point of external appearance stability at high temperature. As the two types of combinations, a combination of glycerin and propylene glycol, glycerin and butylene glycol, or glycerin and polyethylene glycol (particularly polyethylene glycol # 400) is preferable. As the three combinations, a combination of glycerin, propylene glycol and polyethylene glycol, or glycerin, propylene glycol and butylene glycol is preferable.
成分(C)の総配合量は、組成物全体の5〜15%であり、低温及び高温での外観安定性及び使用時、使用後の口腔内のべたつき感の点で6〜13%が好ましい。配合量が5%未満では高温及び低温での外観安定性を維持するのが難しく、白濁する場合がある。15%を超えると、低温での保存時にアニオン性界面活性剤が析出したり、また使用時、使用後のべたつき感が生じる場合がある。 The total amount of component (C) is 5 to 15% of the entire composition, and is preferably 6 to 13% in terms of appearance stability at low and high temperatures and stickiness in the oral cavity after use at the time of use. . If the blending amount is less than 5%, it is difficult to maintain the appearance stability at high and low temperatures, and it may become cloudy. If it exceeds 15%, an anionic surfactant may precipitate during storage at a low temperature, or stickiness after use may occur during use.
更に、成分(C)として、グリセリンを配合する場合は組成物全体の0.5%以上、プロピレングリコールを配合する場合は組成物全体の1%以上、ブチレングリコールを配合する場合は組成物全体の1%以上、平均分子量190〜630のポリエチレングリコールは組成物全体の1%以上配合することが好ましい。 Furthermore, as a component (C), when blending glycerin, 0.5% or more of the whole composition, when blending propylene glycol, 1% or more of the whole composition, and when blending butylene glycol, 1% or more of polyethylene glycol having an average molecular weight of 190 to 630 is preferably blended in an amount of 1% or more of the entire composition.
本発明で使用されるイソプロピルメチルフェノールの配合量は、歯周病原性バイオフィルムの浸透殺菌効果を発揮させる点で、組成物全体の0.01〜0.1%、特に0.02〜0.08%とすることが好ましく、配合量が0.01%未満であるとバイオフィルムに対して殺菌力を発揮できない場合があり、0.1%を超えると白濁、外観安定性を損ねる場合がある。 The amount of isopropylmethylphenol used in the present invention is 0.01 to 0.1% of the entire composition, particularly 0.02 to 0.0. Preferably, the content is less than 0.01%. If the blending amount is less than 0.01%, the sterilizing power may not be exerted on the biofilm. If it exceeds 0.1%, the cloudiness and appearance stability may be impaired. .
本発明の液体口腔用組成物では、使用性と味の点から、水分量は、組成物全量の70%以上であり、更に使用感の点から80%以上とすることが好ましい。なお、水分量の上限値は、上記(A)〜(C)成分及びイソプロピルメチルフェノールの下限配合量の合計とが100%となる量、即ち94.84%とすることが好ましい。 In the liquid oral composition of the present invention, the water content is 70% or more of the total amount of the composition from the viewpoint of usability and taste, and is preferably 80% or more from the viewpoint of the feeling of use. In addition, it is preferable that the upper limit of the amount of water is set to an amount at which the sum of the lower limit amounts of the components (A) to (C) and isopropylmethylphenol is 100%, that is, 94.84%.
更に、本発明の液体口腔用組成物には、浮遊菌への殺菌力を向上させる目的で(D)トリクロサンを配合することができる。その配合量は、組成物全体の0.01〜0.1%、特に0.02〜0.08%とすることが好ましく、配合量が0.01%未満であると浮遊菌に対して殺菌力を発揮できない場合があり、0.1%を超えると白濁、外観安定性を損ねる場合がある。 Furthermore, (D) triclosan can be mix | blended with the liquid oral cavity composition of this invention in order to improve the bactericidal power to a floating microbe. The blending amount is preferably 0.01 to 0.1%, particularly 0.02 to 0.08% of the entire composition, and if the blending amount is less than 0.01%, it is sterilized against airborne bacteria. In some cases, the strength cannot be exhibited, and when it exceeds 0.1%, cloudiness and appearance stability may be impaired.
本発明の液体口腔用組成物は、実質的にエタノールを含まないものである。ここで、「実質的にエタノールを含まない」とは、組成物中のエタノール量が組成物全体に対して100ppm以下、好ましくは50ppm以下、特に好ましくは10ppm以下のものであり、下限値は0ppmである。なお、本発明の液体口腔用組成物は、エタノールを無配合であるが、組成物中に配合される香料中に原料由来のエタノールが微量含有される場合などがあるため、これらの理由を考慮した上で、香料中などに微量含有されるエタノール以外にエタノールを含まないものである。 The liquid oral composition of the present invention is substantially free of ethanol. Here, "substantially free of ethanol", 100 ppm or less amount of ethanol in the composition is relative to the total composition, preferably 50ppm or less, particularly preferably of 10ppm or less, the lower limit 0ppm It is. The liquid oral composition of the present invention contains no ethanol, but there are cases where a small amount of raw material-derived ethanol is contained in the fragrance compounded in the composition. In addition, it contains no ethanol other than a small amount of ethanol contained in the perfume.
本発明の液体口腔用組成物は、洗口剤、液体歯磨などとして調製、適用することができるが、本発明の液体口腔用組成物には、上記成分以外に、その剤型に応じて適宜な任意成分を配合することができ、例えば、上記成分以外の湿潤剤、増粘剤、pH調整剤、防腐剤、甘味剤、香料、界面活性剤、有効成分、着色料等を含有できる。 The liquid oral cavity composition of the present invention can be prepared and applied as a mouthwash, liquid dentifrice, etc., but the liquid oral cavity composition of the present invention is appropriately selected according to its dosage form in addition to the above components. In addition to the above components, for example, wetting agents, thickeners, pH adjusters, preservatives, sweeteners, fragrances, surfactants, active ingredients, coloring agents, and the like can be contained.
上記した成分(C)以外の湿潤剤としては、ソルビトール、エチレングリコール、キシリット、マルチット、ラクチット等を含有することができる。なお、これら成分(C)以外の湿潤剤の配合量は組成物全体に対して0〜6%が好ましい。 As the wetting agent other than the above component (C), sorbitol, ethylene glycol, xylit, malt, lactit and the like can be contained. In addition, 0-6% of the compounding quantity of wetting agents other than these components (C) is preferable with respect to the whole composition.
増粘剤としては、キサンタンガム、アルギン酸ナトリウム、ポリビニルアルコール、ヒドロキシエチルセルロース、カラギナン、カルボキシメチルセルロースナトリウム等を本発明の効果を妨げない範囲で使用することができる。 As the thickener, xanthan gum, sodium alginate, polyvinyl alcohol, hydroxyethyl cellulose, carrageenan, sodium carboxymethyl cellulose and the like can be used as long as the effects of the present invention are not hindered.
pH調整剤としては、フタル酸、リン酸、クエン酸、コハク酸、酢酸、フマル酸、リンゴ酸及び炭酸並びにそれらのカリウム塩、ナトリウム塩及びアンモニウム塩、リボ核酸及びその塩類、更に水酸化ナトリウムなどの少なくとも1種を用いることができ、特にリン酸、クエン酸とそれらのナトリウム塩を組み合わせたものが好ましい。
特に、本発明の液体口腔用組成物は、25℃におけるpHを5.5〜7.5に調整することが好ましく、pH調整剤として、リン酸二水素ナトリウムとリン酸一水素ナトリウムあるいはクエン酸とクエン酸ナトリウムを組み合わせたものを用いることが好ましい。Examples of pH adjusters include phthalic acid, phosphoric acid, citric acid, succinic acid, acetic acid, fumaric acid, malic acid and carbonic acid and their potassium, sodium and ammonium salts, ribonucleic acid and its salts, and sodium hydroxide. At least one of the above can be used, and a combination of phosphoric acid, citric acid and their sodium salts is particularly preferred.
In particular, the liquid oral composition of the present invention preferably adjusts the pH at 25 ° C. to 5.5 to 7.5. As a pH adjuster, sodium dihydrogen phosphate and sodium monohydrogen phosphate or citric acid are used. It is preferable to use a combination of citrate and sodium citrate.
防腐剤としては、安息香酸ナトリウム、メチルパラベン、エチルパラベン、プロピルパラベン、ブチルパラベン、塩酸セチルピリジニウム、塩酸アルキルジアミノエチルグリシン、ソルビン酸カリウム等を含有することができる。 Examples of the preservative may include sodium benzoate, methyl paraben, ethyl paraben, propyl paraben, butyl paraben, cetyl pyridinium hydrochloride, alkyldiaminoethyl glycine hydrochloride, potassium sorbate, and the like.
甘味剤としては、サッカリンナトリウム、ステビオサイト、スクラロース、還元パラチノース、エリスリトール等を含有することができる。 As the sweetener, saccharin sodium, steviosite, sucralose, reduced palatinose, erythritol and the like can be contained.
香料としては、ペパーミント油、スペアミント油、ユーカリ油、ウィンターグリーン油、クローブ油、タイム油、セージ油、カルダモン油、ローズマリー油、マジョラム油、レモン油、ナツメグ油、ラベンダー油、パラクレス油等の天然精油、及びl−カルボン、1,8−シネオール、メチルサリシレート、オイゲノール、チモール、リナロール、リモネン、メントン、メンチルアセテート、シトラール、カンファー、ボルネオール、ピネン、スピラントール等の上記天然精油中に含まれる香料成分、また、エチルアセテート、エチルブチレート、イソアミルアセテート、ヘキサナール、ヘキセナール、メチルアンスラニレート、エチルメチルフェニルグリシデート、ベンツアルデヒド、バニリン、エチルバニリン、フラネオール、マルトール、エチルマルトール、ガンマ又はデルタデカラクトン、ガンマ又はデルタウンデカラクトン、N−エチル−p−メンタン−3−カルボキサミド、メンチルラクテート、エチレングリコール−l−メンチルカーボネート等の香料成分、更には、いくつかの香料成分や天然精油を組み合わせてなる、アップル、バナナ、ストロベリー、ブルーベリー、メロン、ピーチ、パイナップル、グレープ、マスカット、ワイン、チェリー、スカッシュ、コーヒー、ブランデー、ヨーグルト等の調合フレーバーの1種又は2種以上を本発明の効果を妨げない範囲で、組成物中に実質的にエタノールを含まないように使用することができる。上記香料の配合量は、組成物全体の0.00001〜3%が好適である。 Natural flavors such as peppermint oil, spearmint oil, eucalyptus oil, wintergreen oil, clove oil, thyme oil, sage oil, cardamom oil, rosemary oil, marjoram oil, lemon oil, nutmeg oil, lavender oil, paracres oil, etc. Essential oils, and perfume ingredients contained in the above natural essential oils such as l-carvone, 1,8-cineole, methyl salicylate, eugenol, thymol, linalool, limonene, menthone, menthyl acetate, citral, camphor, borneol, pinene, spirantol, etc. Ethyl acetate, ethyl butyrate, isoamyl acetate, hexanal, hexenal, methyl anthranilate, ethyl methyl phenylglycidate, benzaldehyde, vanillin, ethyl vanillin, furaneol, maltol Perfume ingredients such as ethyl maltol, gamma or delta decalactone, gamma or deltown decalactone, N-ethyl-p-menthane-3-carboxamide, menthyl lactate, ethylene glycol-l-menthyl carbonate, One or more kinds of blended flavors such as apple, banana, strawberry, blueberry, melon, peach, pineapple, grape, muscat, wine, cherry, squash, coffee, brandy, yogurt, etc. Can be used so that ethanol is not substantially contained in the composition as long as the effect of the present invention is not hindered. The blending amount of the fragrance is preferably 0.00001 to 3% of the entire composition.
上記成分(A)及び(B)以外の界面活性剤として、ラウロイルメチルタウリン、アシルアミノ酸塩、ドデシルベンゼンスルホン酸ナトリウム、α−スルホ脂肪酸アルキルエステル・ナトリウム、アルキルリン酸エステル塩等のアニオン性界面活性剤、アルキルジメチルアミノ酢酸ベタイン、脂肪酸アミドプロピルジメチルアミノ酢酸ベタインなどの酢酸ベタイン型両性界面活性剤、N−脂肪酸アシル−N−カルボキシメチル−N−ヒドロキシエチルエチレンジアミン塩などのイミダゾリン型両性界面活性剤、N−脂肪酸アシル−L−アルギネート塩等のアミノ酸型界面活性剤などを単独又は組み合わせて、本発明の効果を妨げない範囲で使用することができる。上記成分(A),(B)以外の界面活性剤を配合する場合、その配合量は組成物全体の0.01〜5%が好ましい。 As surfactants other than the above components (A) and (B), anionic surfactants such as lauroylmethyl taurine, acylamino acid salts, sodium dodecylbenzenesulfonate, α-sulfo fatty acid alkyl ester / sodium, and alkyl phosphate ester salts Agents, betaine acetate type amphoteric surfactants such as alkyldimethylaminoacetic acid betaine, fatty acid amidopropyldimethylaminoacetic acid betaine, imidazoline type amphoteric surfactants such as N-fatty acid acyl-N-carboxymethyl-N-hydroxyethylethylenediamine salt, Amino acid surfactants such as N-fatty acid acyl-L-alginate salts can be used alone or in combination as long as the effects of the present invention are not impaired. When a surfactant other than the components (A) and (B) is blended, the blending amount is preferably 0.01 to 5% of the entire composition.
上記イソプロピルメチルフェノール、トリクロサン以外の有効成分としては、トラネキサム酸、イプシロン−アミノカプロン酸などの抗炎症剤、デキストラナーゼ、アミラーゼ、プロテアーゼ、ムタナーゼ、リゾチーム、溶菌酵素、リテックエンザイム等の酵素、フッ化ナトリウム、モノフルオロリン酸ナトリウム、フッ化第一錫等のフッ化物、アルミニウムクロルヒドロキシアラントイン、アラントイン、アズレン、塩化リゾチーム、アスコルビン酸等のビタミンC類、ジヒドロコレステロール、グリチルレチン塩類、グリチルレチン酸類、ヒドロコレステロール、クロロフィル、銅クロロフィリンナトリウム、タイム、オウゴン、チョウジ、ハマメリス等の植物抽出物、グルコン酸銅、カロペプタイド、ポリリン酸ナトリウム、水溶性無機リン酸化合物、ポリビニルピロリドン、歯石防止剤、歯垢防止剤、硝酸カリウム、乳酸アルミニウム等を添加することができる。なお、これらの有効成分の配合量は、本発明の効果を妨げない範囲で有効量とすることができる。 Active ingredients other than isopropylmethylphenol and triclosan include anti-inflammatory agents such as tranexamic acid and epsilon-aminocaproic acid, enzymes such as dextranase, amylase, protease, mutanase, lysozyme, lytic enzyme, lytechenzyme, sodium fluoride , Fluorides such as sodium monofluorophosphate and stannous fluoride, vitamin C such as aluminum chlorohydroxy allantoin, allantoin, azulene, lysozyme chloride, ascorbic acid, dihydrocholesterol, glycyrrhetin salts, glycyrrhetinic acid, hydrocholesterol, chlorophyll , Copper chlorophyllin sodium, Thyme, Ogon, Clove, Hamamelis plant extract, Copper gluconate, Caropeptide, Sodium polyphosphate, Water-soluble Phosphoric acid compounds, polyvinylpyrrolidone, anti-tartar agents, anti-plaque agents, potassium nitrate, may be added to aluminum lactate and the like. In addition, the compounding quantity of these active ingredients can be made into an effective quantity in the range which does not prevent the effect of this invention.
着色料としては、青色1号、緑色3号、黄色4号、赤色105号など安全性の高い水溶性色素を添加することができる。 As a colorant, a highly safe water-soluble dye such as Blue No. 1, Green No. 3, Yellow No. 4, Red No. 105 can be added.
本発明の液体口腔用組成物を収容する容器としては、PET(ポリエチレンテレフタレート)、ガラス、ポリプロピレン、ポリエチレンが使用できるが、非イオン性殺菌剤及び香料の吸着抑制の点からPETとガラスの使用が好ましい。 PET (polyethylene terephthalate), glass, polypropylene, and polyethylene can be used as the container for storing the liquid oral cavity composition of the present invention. However, the use of PET and glass is preferred in terms of suppressing adsorption of nonionic fungicides and fragrances. preferable.
以下、実験例、実施例及び比較例に基づいて本発明をより詳細に説明するが、本発明はこれらの実施例により制限されるものではない。
これらの液体口腔用組成物の調製には、イソプロピルメチルフェノール(大阪化成製)、ラウリル硫酸ナトリウム(東邦化学工業社製)、ミリスチル硫酸ナトリウム(日光ケミカルズ社製)、セチル硫酸ナトリウム(日光ケミカルズ社製)、ラウロイルサルコシンナトリウム(川研ファインケミカル社製)、ミリストイルサルコシンナトリウム(日光ケミカルズ社製)、パルミトイルサルコシンナトリウム(日光ケミカルズ社製)、ポリオキシエチレン(40)硬化ヒマシ油(日光ケミカルズ社製)、ポリオキシエチレン(60)硬化ヒマシ油(日光ケミカルズ社製)、ポリオキシエチレン(100)硬化ヒマシ油(日光ケミカルズ社製)、ポリオキシエチレン(40)ステアリルエーテル(日本エマルジョン社製)、ポリオキシエチレン(40)セチルエーテル(日本エマルジョン社製)、ポリオキシエチレン(20)セチルエーテル(日本エマルジョン社製)、ポリオキシエチレン(10)セチルエーテル(日光ケミカルズ社製)、グリセリン(85%、阪本薬品工業社製)、プロピレングリコール(旭硝子社製)、ブチレングリコール(ダイセル化学工業社製)、ポリエチレングリコール#200(マクロゴール200、三洋化成社製)、ポリエチレングリコール#400(ライオン化学製)、ポリエチレングリコール#600(ライオン化学社製)、トリクロサン(チバ・スペシャルティ・ケミカルズ社製)、クエン酸(扶桑化学社製)、クエン酸ナトリウム(扶桑化学社製)を用いた。また、ラウリルリン酸ナトリウム(日光ケミカルズ社製)、ポリオキシエチレン(2)ラウリルエーテル硫酸ナトリウム(日光ケミカルズ社製)、ポリオキシエチレン(30)硬化ヒマシ油(日光ケミカルズ社製)、ポリオキシエチレン(7)セチルエーテル(日本エマルジョン社製)、エタノール(日本アルコール販売社製)を比較例に使用した。なお、表中のPOEはポリオキシエチレンを、PEGはポリエチレングリコールを示し、下記に示す%は特に断らない限りいずれも質量%を意味する。EXAMPLES Hereinafter, although this invention is demonstrated in detail based on an experiment example, an Example, and a comparative example, this invention is not restrict | limited by these Examples.
For preparation of these liquid oral compositions, isopropylmethylphenol (manufactured by Osaka Kasei), sodium lauryl sulfate (manufactured by Toho Chemical Industries), sodium myristyl sulfate (manufactured by Nikko Chemicals), sodium cetyl sulfate (manufactured by Nikko Chemicals) ), Sodium lauroyl sarcosine (manufactured by Kawaken Fine Chemicals), sodium myristoyl sarcosine (manufactured by Nikko Chemicals), sodium palmitoyl sarcosine (manufactured by Nikko Chemicals), polyoxyethylene (40) hydrogenated castor oil (manufactured by Nikko Chemicals), poly Oxyethylene (60) hydrogenated castor oil (Nikko Chemicals), polyoxyethylene (100) hydrogenated castor oil (Nikko Chemicals), polyoxyethylene (40) stearyl ether (Nihon Emulsion), polyoxyethylene ( 0) Cetyl ether (manufactured by Nippon Emulsion), polyoxyethylene (20) cetyl ether (manufactured by Nippon Emulsion), polyoxyethylene (10) cetyl ether (manufactured by Nikko Chemicals), glycerin (85%, Sakamoto Yakuhin Kogyo Co., Ltd.) ), Propylene glycol (manufactured by Asahi Glass Co., Ltd.), butylene glycol (manufactured by Daicel Chemical Industries, Ltd.), polyethylene glycol # 200 (macrogor 200, manufactured by Sanyo Chemical Co., Ltd.), polyethylene glycol # 400 (manufactured by Lion Chemical), polyethylene glycol # 600 (Manufactured by Lion Chemical Co., Ltd.), triclosan (manufactured by Ciba Specialty Chemicals Co., Ltd.), citric acid (manufactured by Fuso Chemical Co., Ltd.), and sodium citrate (manufactured by Fuso Chemical Co., Ltd.) were used. Also, sodium lauryl phosphate (manufactured by Nikko Chemicals), polyoxyethylene (2) sodium lauryl ether sulfate (manufactured by Nikko Chemicals), polyoxyethylene (30) hydrogenated castor oil (manufactured by Nikko Chemicals), polyoxyethylene ( 7) Cetyl ether (manufactured by Nippon Emulsion Co., Ltd.) and ethanol (manufactured by Nippon Alcohol Sales Co., Ltd.) were used as comparative examples. In the table, POE represents polyoxyethylene, PEG represents polyethylene glycol, and% shown below means mass% unless otherwise specified.
〔実験例1〕
表1〜6に示す組成の液体口腔用組成物を常法により調製し、下記方法でモデルバイオフィルムに対する浸透殺菌効果を評価した。結果を表1〜6に示す。
(1)モデル歯周病原性バイオフィルムの作製方法
直径7mm×厚さ3.5mmのハイドロキシアパタイト(HA)板(旭光学社製)を0.45μmのフィルターでろ過したヒト無刺激唾液で4時間処理したものをモデルバイオフィルム作製の担体に用いた。培養液は、トリプチケースソイブロス(Difco製)30gを1Lの精製水に溶解した液にヘミン(シグマ社製)5mg、メナジオン(シグマ社製)0.5mgを添加したものを用いた。モデルバイオフィルムを作製するために、口腔常在細菌としてストレプトコッカス ゴルドニアイ ATC51656株及びアクチノマイセス ナエスランディ ATCC51655株、病原性細菌としてポルフィロモナス ジンジバリス ATCC33277株を用いた。これら3菌種をそれぞれ2×107cfu/mL(cfu:colony forming units)になるように上述の培養液に接種し、唾液処理したHA担体と共に37℃、嫌気条件下(5%炭酸ガス、95%窒素)で2週間連続培養(培養液の置換率は10Vol%とした)を行い、HA表面に3菌種混合のモデルバイオフィルムを形成させた。[Experimental Example 1]
Liquid oral compositions having the compositions shown in Tables 1 to 6 were prepared by a conventional method, and the penetration sterilization effect on the model biofilm was evaluated by the following method. The results are shown in Tables 1-6.
(1) Method for producing model periodontopathic biofilm 4 hours with human unstimulated saliva obtained by filtering a hydroxyapatite (HA) plate (manufactured by Asahi Optical Co., Ltd.) having a diameter of 7 mm and a thickness of 3.5 mm with a 0.45 μm filter. The treated product was used as a carrier for preparing a model biofilm. The culture solution was prepared by adding 5 mg hemin (Sigma) and 0.5 mg menadione (Sigma) to a solution obtained by dissolving 30 g of trypticase soy broth (Difco) in 1 L of purified water. In order to produce a model biofilm, Streptococcus gordonii ATC 51656 strain and Actinomyces naeslandi ATCC 51655 strain were used as oral resident bacteria, and Porphyromonas gingivalis ATCC 33277 strain was used as a pathogenic bacterium. These three bacterial species were inoculated into the above-mentioned culture solution so as to be 2 × 10 7 cfu / mL (cfu: colony forming units), respectively, at 37 ° C. under anaerobic conditions (5% carbon dioxide gas, 95% nitrogen) was continuously cultured for 2 weeks (the replacement rate of the culture medium was set to 10 Vol%) to form a model biofilm mixed with three bacterial species on the HA surface.
(2)モデルバイオフィルムに対する浸透殺菌効果
形成させたモデルバイオフィルムを表1〜5に示したサンプル2mLに3分間浸漬し、滅菌生理食塩水1mLで6回洗浄した。その後、滅菌生理食塩水4mLで超音波処理(200μA、10秒間)によりモデルバイオフィルムを分散し、10%綿羊脱繊血含有トリプチケースソイ寒天平板(Difco製)及び硫酸カナマイシン(200mg/L:シグマ社製)含有トリプチケースソイ血液寒天平板に50μL塗沫し、嫌気性条件下で培養した。生育したコロニーを計測し、残存するポルフィロモナス ジンジバリス菌の菌数(cfu)を求め、下記基準に則り、判定した。
浸透殺菌効果判定基準
◎:生菌数が106未満
○:生菌数が106以上107未満
△:生菌数が107以上108未満
×:生菌数が108以上(2) Osmotic sterilization effect on model biofilm The formed model biofilm was immersed in 2 mL of the sample shown in Tables 1 to 3 for 3 minutes and washed 6 times with 1 mL of sterile physiological saline. Thereafter, the model biofilm was dispersed by sonication (200 μA, 10 seconds) with 4 mL of sterilized physiological saline, a 10% cotton defibrinated blood-containing trypticase soy agar plate (manufactured by Difco) and kanamycin sulfate (200 mg / L: 50 μL was spread on a tripty case soy blood agar plate containing Sigma) and cultured under anaerobic conditions. The grown colonies were counted, and the number of remaining Porphyromonas gingivalis bacteria (cfu) was determined and determined according to the following criteria.
Penetration bactericidal effect criteria ◎: viable count is less than 10 6 ○: viable count is less than 10 6 or more 10 7 △: viable count is 10 7 to 10 8 less ×: the viable cell count 10 8 or more
〔実験例2〕
表1〜6に示す組成の液体口腔用組成物について、下記方法で外観安定性を評価した。結果を表1〜6に示す。
(1)外観安定性
表1〜6に示したサンプルを満注量450mLのPET容器に450mL充填し、−5℃又は50℃恒温槽に1ヶ月保存後の外観安定性を下記基準に則り、目視判定した。[Experimental example 2]
About the liquid oral composition of the composition shown to Tables 1-6, the external appearance stability was evaluated with the following method. The results are shown in Tables 1-6.
(1) Appearance stability 450 mL of the sample shown in Tables 1 to 6 is filled in a 450 mL PET container, and the appearance stability after 1 month storage in a -5 ° C or 50 ° C constant temperature bath is in accordance with the following criteria: Visual judgment was made.
外観安定性評価基準
◎:初期品と比較し、変化が認められない。
○:ごくわずかなオリが認められるが問題ない。
△:微濁が認められる。
×:かなりの白濁又は沈澱物が認められる。 Appearance stability evaluation standard A : No change is observed compared to the initial product.
○: A slight amount of orientation is recognized but there is no problem.
Δ: Slight turbidity is observed.
X: Considerable cloudiness or precipitate is observed.
〔実験例3〕
表1〜6に示す組成の液体口腔用組成物について、下記方法で使用感を評価した。結果を表1〜6に示す。
(1)使用感評価
表1〜6に示したサンプル10mLを口に含み、30秒間すすいだ後、洗口後の刺激のなさ、べたつき感について対照品(比較例6又は9)との比較で下記の4段階で評価し、10名の平均点を次の基準に従い、◎、○、△、×で表に示した。
使用感評価基準
◎:平均点3.0点を超えて4.0点以下
○:平均点2.0点を超えて3.0点以下
△:平均点1.5点以上2.0点以下
×:平均点1.0点以上1.5点未満[Experimental Example 3]
About the liquid oral cavity composition of the composition shown to Tables 1-6, the usability | use_condition was evaluated with the following method. The results are shown in Tables 1-6.
(1) Evaluation of feeling of use 10 mL of the samples shown in Tables 1 to 6 were included in the mouth, rinsed for 30 seconds, and after the mouthwash, no irritation and stickiness were compared with the control product (Comparative Example 6 or 9). Evaluation was made in the following four stages, and the average score of 10 people was shown in the table as ◎, ○, Δ, × according to the following criteria.
Usability Evaluation Criteria ◎: Average point exceeding 3.0 point and 4.0 point or less ○: Average point exceeding 2.0 point and 3.0 point or less Δ: Average point 1.5 point or more and 2.0 point or less ×: Average point 1.0 point or more and less than 1.5 point
洗口後の刺激のなさ(対照品:比較例6)
4:対照品の刺激と比較して顕著に刺激が低かった。
3:対照品の刺激と比較してやや刺激が低く問題のないレベルであった。
2:対照品の刺激と比較して同等な刺激が認められた。
1:対照品の刺激と比較して刺激が認められた。
洗口後のべたつき感のなさ(対照品:比較例9)
4:対照品のべたつきと比較してほとんどべたつきが認められなかった。
3:対照品のべたつきと比較してややべたつきが認められず問題のないレベルであった。
2:対照品のべたつきと比較して同等のべたつきが認められた。
1:対照品のべたつきと比較してべたつきが認められた。 No irritation after mouthwash (Control: Comparative Example 6)
4: The irritation was significantly lower than that of the control product.
3: Compared with the stimulus of the control product, the stimulus was slightly lower and there was no problem.
2: Stimulation equivalent to that of the control product was observed.
1: Stimulation was observed in comparison with the control product.
No stickiness after mouthwash (Control: Comparative Example 9)
4: The stickiness was hardly recognized compared with the stickiness of the control product.
3: Compared with the stickiness of the control product, a little stickiness was not recognized, and the level was satisfactory.
2: The stickiness equivalent to the stickiness of the control product was recognized.
1: Stickiness was recognized as compared with the stickiness of the control product.
〔実験例4〕
表6に示す組成の液体口腔用組成物について、下記方法で浮遊菌に対する殺菌効果を評価した。結果を表6に示す。
(1)浮遊菌に対する殺菌効果
使用した菌液は培養液としてトリプチケースソイブロス(Difco製)30gを1Lの精製水に溶解したものを、口腔常在細菌としてアクチノマイセス ナエスランディ ATCC51655株を用い、37℃、嫌気条件下(5%炭酸ガス、95%窒素)で1日培養した液の550nmでの透過度が20になるように生理食塩水を加えて調製した。表6に示したサンプル2.7mLに菌液0.3mLを加え、撹拌後、37℃で1分間反応させ、再び撹拌後、予め2.7mLの培養液の入った試験管を5本用意し、その1番目の試験管に0.3mLを加え、撹拌した。この液0.3mLを採取し、2番目の試験管に加え、撹拌した。この操作を同様に3〜5番目の試験管に順に行った。1,3,5番目の試験管中の培養液を撹拌後、10%綿羊脱繊血含有トリプチケースソイ寒天平板(Difco製)に50μL塗沫し、嫌気条件下で培養した。生育したコロニーを計測し、残存するアクチノマイセス ナエスランディ菌の菌数(cfu)を求め、下記基準に則り、判定した。
浮遊菌に対する殺菌効果の判定基準
○:生菌数が103未満
△:生菌数が103以上104未満
×:生菌数が104以上
[Experimental Example 4]
About the composition for liquid oral cavity of the composition shown in Table 6, the bactericidal effect with respect to an airborne microbe was evaluated by the following method. The results are shown in Table 6.
(1) Bactericidal effect against airborne bacteria The bacterial solution used was a solution obtained by dissolving 30 g of Trypticase Soy Broth (Difco) in 1 L of purified water as a culture solution, and using Actinomyces naesrandi ATCC 51655 strain as oral resident bacteria. It was prepared by adding physiological saline so that the permeability at 550 nm of a solution cultured for one day at 37 ° C. under anaerobic conditions (5% carbon dioxide gas, 95% nitrogen) was 20. Add 0.3 mL of the bacterial solution to 2.7 mL of the sample shown in Table 6, and after stirring, react at 37 ° C. for 1 minute. After stirring again, prepare five test tubes containing 2.7 mL of the culture solution in advance. Then, 0.3 mL was added to the first test tube and stirred. 0.3 mL of this solution was collected, added to the second test tube, and stirred. This operation was similarly performed on the third to fifth test tubes in the same manner. After stirring the culture solution in the first, third, and fifth test tubes, 50 μL was smeared on a tripty case soy agar plate (manufactured by Difco) containing 10% cotton defibrinated blood and cultured under anaerobic conditions. The grown colonies were counted, and the number of remaining Actinomyces naeslandi bacteria (cfu) was determined and determined according to the following criteria.
Criteria for determination of bactericidal effect against airborne bacteria ○: Number of viable bacteria is less than 10 3 Δ: Number of viable bacteria is 10 3 or more and less than 10 4 ×: Number of viable bacteria is 10 4 or more
次に、下記実施例の液体口腔用組成物を常法により調製し、上記と同様に評価したところ、いずれも優れた病原性バイオフィルムへの浸透殺菌力、浮遊菌殺菌力(トリクロサン配合組成である実施例22,23のみ評価)、外観安定性、使用感を有していた。なお、香料は、下記表7に示す組成の香料を使用した。 Next, liquid oral compositions of the following examples were prepared by a conventional method and evaluated in the same manner as described above. All of them were excellent in penetrating and bactericidal power to pathogenic biofilms, Only certain Examples 22 and 23 were evaluated), and had appearance stability and usability. In addition, the fragrance | flavor of the composition shown in following Table 7 was used for the fragrance | flavor.
〔実施例22〕 洗口剤
イソプロピルメチルフェノール 0.05%
A ラウリル硫酸ナトリウム 0.1
B ポリオキシエチレン(60)硬化ヒマシ油 0.3
C グリセリン 2
プロピレングリコール 4
PEG#400 3
D トリクロサン 0.05
トラネキサム酸 0.04
グリチルリチン酸ジカリウム 0.06
クエン酸 0.06
クエン酸ナトリウム 0.5
パラオキシ安息香酸メチル 0.1
サッカリンナトリウム 0.01
香料A 0.2
水 残
計 100.0%[Example 22] Mouthwash isopropylmethylphenol 0.05%
A Sodium lauryl sulfate 0.1
B polyoxyethylene (60) hydrogenated castor oil 0.3
C Glycerin 2
Propylene glycol 4
PEG # 400 3
D Triclosan 0.05
Tranexamic acid 0.04
Dipotassium glycyrrhizinate 0.06
Citric acid 0.06
Sodium citrate 0.5
Methyl paraoxybenzoate 0.1
Saccharin sodium 0.01
Fragrance A 0.2
Water remaining
Total 100.0%
〔実施例23〕 洗口剤
イソプロピルメチルフェノール 0.05%
A ラウロイルサルコシンナトリウム 0.1
B ポリオキシエチレン(60)硬化ヒマシ油 0.3
C グリセリン 2
プロピレングリコール 4
PEG#400 5
D トリクロサン 0.02
キシリトール 5
ε−アミノカプロン酸 0.03
安息香酸ナトリウム 0.3
クエン酸 0.03
クエン酸ナトリウム 0.25
香料B 0.2
水 残
計 100.0%[Example 23] Mouthwash isopropylmethylphenol 0.05%
A Lauroyl sarcosine sodium 0.1
B polyoxyethylene (60) hydrogenated castor oil 0.3
C Glycerin 2
Propylene glycol 4
PEG # 400 5
D Triclosan 0.02
Xylitol 5
ε-aminocaproic acid 0.03
Sodium benzoate 0.3
Citric acid 0.03
Sodium citrate 0.25
Fragrance B 0.2
Water remaining
Total 100.0%
〔実施例24〕 洗口剤
イソプロピルメチルフェノール 0.05%
A ラウロイルサルコシンナトリウム 0.1
B ポリオキシエチレン(100)硬化ヒマシ油 0.3
C グリセリン 3
プロピレングリコール 4
ブチレングリコール 5
キシリトール 4
酢酸dl−α−トコフェノール 0.05
フッ化ナトリウム 0.1
クエン酸 0.03
クエン酸ナトリウム 0.25
香料C 0.3
水 残
計 100.0%[Example 24] Mouthwash isopropylmethylphenol 0.05%
A Lauroyl sarcosine sodium 0.1
B Polyoxyethylene (100) hydrogenated castor oil 0.3
C Glycerin 3
Propylene glycol 4
Butylene glycol 5
Xylitol 4
Acetic acid dl-α-tocophenol 0.05
Sodium fluoride 0.1
Citric acid 0.03
Sodium citrate 0.25
Fragrance C 0.3
Water remaining
Total 100.0%
〔実施例25〕 洗口剤
イソプロピルメチルフェノール 0.1%
A ミリスチル硫酸ナトリウム 0.2
B ポリオキシエチレン(80)硬化ヒマシ油 0.5
C グリセリン 3
プロピレングリコール 4
キシリトール 4
アスパルテーム 0.02
ピロリン酸ナトリウム 0.17
ポリ燐酸ナトリウム 0.02
クエン酸 0.1
クエン酸ナトリウム 0.8
香料D 0.4
水 残
計 100.0%[Example 25] Mouthwash isopropylmethylphenol 0.1%
A Sodium myristyl sulfate 0.2
B Polyoxyethylene (80) hydrogenated castor oil 0.5
C Glycerin 3
Propylene glycol 4
Xylitol 4
Aspartame 0.02
Sodium pyrophosphate 0.17
Sodium polyphosphate 0.02
Citric acid 0.1
Sodium citrate 0.8
Fragrance D 0.4
Water remaining
Total 100.0%
〔実施例26〕 洗口剤
イソプロピルメチルフェノール 0.06%
A ミリストイルサルコシンナトリウム 0.2
B ポリオキシエチレン(20)セチルエーテル 0.4
C グリセリン 3
プロピレングリコール 4
PEG#600 5
サッカリン 0.01
アスパルテーム 0.02
銅クロロフィンナトリウム 0.01
デキストラナーゼ 0.02
アスコルビン酸ナトリウム 0.03
クエン酸 0.06
クエン酸ナトリウム 0.5
香料E 0.2
水 残
計 100.0%[Example 26] Mouthwashing isopropylmethylphenol 0.06%
A Myristoyl sarcosine sodium 0.2
B polyoxyethylene (20) cetyl ether 0.4
C Glycerin 3
Propylene glycol 4
PEG # 600 5
Saccharin 0.01
Aspartame 0.02
Copper chlorofin sodium 0.01
Dextranase 0.02
Sodium ascorbate 0.03
Citric acid 0.06
Sodium citrate 0.5
Fragrance E 0.2
Water remaining
Total 100.0%
〔実施例27〕 洗口剤
イソプロピルメチルフェノール 0.6%
A ラウロイルサルコシンナトリウム 0.15
B ポリオキシエチレン(40)ステアリルエーテル 0.5
C グリセリン 2
プロピレングリコール 4
PEG#400 3
キシリトール 2
ソルビトール 1
アラントイン 0.01
クエン酸 0.03
クエン酸ナトリウム 0.5
香料F 0.2
水 残
計 100.0%[Example 27] Mouthwash isopropylmethylphenol 0.6%
A Lauroyl sarcosine sodium 0.15
B Polyoxyethylene (40) stearyl ether 0.5
C Glycerin 2
Propylene glycol 4
PEG # 400 3
Xylitol 2
Sorbitol 1
Allantoin 0.01
Citric acid 0.03
Sodium citrate 0.5
Fragrance F 0.2
Water remaining
Total 100.0%
Claims (3)
(A)アルキル硫酸ナトリウム及びN−アシルサルコシンナトリウムから選ばれる少なくとも1種のアニオン性界面活性剤、
(B)エチレンオキサイドの平均付加モル数が40〜100モルのポリオキシエチレン硬化ヒマシ油及び炭素鎖長が16〜18でエチレンオキサイドの平均付加モル数が10〜40モルのポリオキシエチレンアルキルエーテルから選ばれる少なくとも1種の非イオン性界面活性剤、
(C)グリセリン、プロピレングリコール、ブチレングリコール、及び平均分子量190〜630のポリエチレングリコールから選ばれる少なくとも1種の湿潤剤を組成物全体の5〜15質量%
を含有し、かつ組成物中の水分量が70質量%以上であると共に、組成物中のエタノール量が100ppm以下であることを特徴とするイソプロピルメチルフェノール含有液体口腔用組成物。A liquid oral composition containing isopropylmethylphenol,
(A) at least one anionic surfactant selected from sodium alkyl sulfate and sodium N-acyl sarcosine,
(B) From polyoxyethylene hydrogenated castor oil having an average addition mole number of ethylene oxide of 40 to 100 moles and polyoxyethylene alkyl ether having a carbon chain length of 16 to 18 and an average addition mole number of ethylene oxide of 10 to 40 moles At least one nonionic surfactant selected,
(C) At least one wetting agent selected from glycerin, propylene glycol, butylene glycol, and polyethylene glycol having an average molecular weight of 190 to 630 is 5 to 15% by mass of the total composition.
And an isopropylmethylphenol-containing liquid oral composition, wherein the amount of water in the composition is 70% by mass or more and the amount of ethanol in the composition is 100 ppm or less .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008522389A JP5136797B2 (en) | 2006-06-23 | 2007-06-11 | Isopropylmethylphenol-containing liquid oral composition |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006173710 | 2006-06-23 | ||
JP2006173710 | 2006-06-23 | ||
PCT/JP2007/061701 WO2007148551A1 (en) | 2006-06-23 | 2007-06-11 | Liquid oral composition containing isopropylmethylphenol |
JP2008522389A JP5136797B2 (en) | 2006-06-23 | 2007-06-11 | Isopropylmethylphenol-containing liquid oral composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2007148551A1 JPWO2007148551A1 (en) | 2009-11-19 |
JP5136797B2 true JP5136797B2 (en) | 2013-02-06 |
Family
ID=38833292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008522389A Active JP5136797B2 (en) | 2006-06-23 | 2007-06-11 | Isopropylmethylphenol-containing liquid oral composition |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP5136797B2 (en) |
KR (1) | KR101380508B1 (en) |
WO (1) | WO2007148551A1 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008110999A (en) * | 2008-02-04 | 2008-05-15 | Mandom Corp | Antibacterial composition and deodorant agent |
JP5470837B2 (en) * | 2008-12-22 | 2014-04-16 | ライオン株式会社 | Liquid oral composition |
JP5568876B2 (en) * | 2009-03-17 | 2014-08-13 | ライオン株式会社 | Teeth demineralization inhibitor and oral composition |
GB0905864D0 (en) * | 2009-04-03 | 2009-05-20 | Glaxo Group Ltd | Novel use |
JP5471318B2 (en) * | 2009-11-06 | 2014-04-16 | ライオン株式会社 | Dentifrice composition |
JP5597969B2 (en) * | 2009-11-06 | 2014-10-01 | ライオン株式会社 | Dentifrice composition |
JP5573111B2 (en) * | 2009-11-06 | 2014-08-20 | ライオン株式会社 | Isopropylmethylphenol-containing liquid oral composition |
WO2011077847A1 (en) * | 2009-12-22 | 2011-06-30 | ライオン株式会社 | Emulsion-type liquid composition for oral cavity, and process for production thereof |
MY157740A (en) * | 2010-03-19 | 2016-07-15 | Lion Corp | Liquid oral composition and method for producing same |
JP5545870B2 (en) * | 2010-12-13 | 2014-07-09 | 花王株式会社 | Biofilm remover |
JP2013121954A (en) * | 2011-11-08 | 2013-06-20 | Earth Chemical Co Ltd | Enhancing agent for collagen density of gum, promoting composition for collagen density of gum, and method for enhancing collagen density of gum |
JP2013245164A (en) * | 2012-05-23 | 2013-12-09 | Kao Corp | Autoinducer-2 inhibitor |
JP5872528B2 (en) * | 2012-12-21 | 2016-03-01 | 花王株式会社 | Method for producing antibacterial agent composition |
KR101932567B1 (en) * | 2015-11-04 | 2018-12-26 | 주식회사 엘지생활건강 | Composition for removal of biofilm |
JP6910867B2 (en) * | 2016-06-27 | 2021-07-28 | サンスター株式会社 | Oral composition |
JP2019048801A (en) * | 2017-09-11 | 2019-03-28 | ライオン株式会社 | Liquid composition for oral cavity |
KR20210014618A (en) * | 2018-05-29 | 2021-02-09 | 라이온 가부시키가이샤 | Oral composition |
JP7403977B2 (en) * | 2018-06-25 | 2023-12-25 | ロート製薬株式会社 | liquid oral composition |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11322554A (en) * | 1998-05-06 | 1999-11-24 | Sunstar Inc | Composition for oral cavity |
JP2006069909A (en) * | 2004-08-31 | 2006-03-16 | Lion Corp | Dentifrice composition |
JP2006124315A (en) * | 2004-10-28 | 2006-05-18 | Lion Corp | Oral composition |
JP2006182663A (en) * | 2004-12-27 | 2006-07-13 | Lion Corp | Liquid composition for oral cavity application |
JP2007106728A (en) * | 2005-10-17 | 2007-04-26 | Lion Corp | Ethanol-free liquid oral composition |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08325126A (en) * | 1995-05-26 | 1996-12-10 | Kao Corp | Composition for oral cavity |
JP2005179231A (en) * | 2003-12-18 | 2005-07-07 | Lion Corp | Liquid composition for oral cavity |
-
2007
- 2007-06-11 KR KR1020087028642A patent/KR101380508B1/en active IP Right Grant
- 2007-06-11 JP JP2008522389A patent/JP5136797B2/en active Active
- 2007-06-11 WO PCT/JP2007/061701 patent/WO2007148551A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11322554A (en) * | 1998-05-06 | 1999-11-24 | Sunstar Inc | Composition for oral cavity |
JP2006069909A (en) * | 2004-08-31 | 2006-03-16 | Lion Corp | Dentifrice composition |
JP2006124315A (en) * | 2004-10-28 | 2006-05-18 | Lion Corp | Oral composition |
JP2006182663A (en) * | 2004-12-27 | 2006-07-13 | Lion Corp | Liquid composition for oral cavity application |
JP2007106728A (en) * | 2005-10-17 | 2007-04-26 | Lion Corp | Ethanol-free liquid oral composition |
Also Published As
Publication number | Publication date |
---|---|
JPWO2007148551A1 (en) | 2009-11-19 |
KR101380508B1 (en) | 2014-04-01 |
KR20090023577A (en) | 2009-03-05 |
WO2007148551A1 (en) | 2007-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5136797B2 (en) | Isopropylmethylphenol-containing liquid oral composition | |
JP4591680B2 (en) | Liquid oral composition | |
JP4957882B2 (en) | Ethanol-free mouthwash composition | |
JP5470837B2 (en) | Liquid oral composition | |
JP5310553B2 (en) | Liquid oral composition and method for improving bactericidal activity of cationic bactericides | |
JP4985905B2 (en) | Liquid oral composition and l-menthol precipitation prevention method | |
JP5359546B2 (en) | Liquid oral composition | |
JP5729252B2 (en) | Oral composition | |
JP2009256228A (en) | Liquid composition for oral cavity | |
JP4873154B2 (en) | Liquid oral composition | |
JP5853387B2 (en) | Liquid oral composition and method for stabilizing and blending ingredients into the composition | |
JP2010143843A (en) | Liquid composition for oral cavity | |
JP5682283B2 (en) | Liquid oral composition | |
CN107205899B (en) | Liquid oral composition | |
JP4952940B2 (en) | Liquid oral composition | |
JP5051347B2 (en) | Liquid oral composition | |
JP5690744B2 (en) | Emulsified liquid oral composition and method for producing the same | |
JP6610001B2 (en) | Liquid oral composition | |
CN111050747A (en) | Dentifrice composition | |
CN109689016B (en) | Liquid oral composition | |
JP2022096463A (en) | Liquid oral composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100223 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120711 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120823 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121017 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121030 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5136797 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151122 Year of fee payment: 3 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |